1015, 926 – 5 Avenue SW
Calgary, AB T2P 0N7
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:
|Mr. Ron Mayron||Exec. Chairman||288k||N/A||1963|
|Ms. Iris Bincovich||CEO & Director||645k||N/A||1969|
|Mr. Yoram Drucker||Founder, Exec. VP of Bus. Devel. & Director||398k||N/A||1965|
|Mr. Nelson Harvey Halpern F.C.A., FCPA||Chief Financial Officer||111k||N/A||1959|
|Mr. Eyal Flom L.L.M., M.B.A.||Director & Company Sec.||N/A||N/A||1967|
|Roni Kamhi||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Moshe Hukaylo||Chief Financial Officer of InnoCan Pharma Ltd.||N/A||N/A||N/A|
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. It engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes to pain relief and treatment of epilepsy and other central nervous system disorders and other indications. The company offers its products under the Shir and Relief & Go brand names. It is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company was incorporated in 2018 and is headquartered in Calgary, Canada.
InnoCan Pharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.